卵巢交界性肿瘤的诊疗现状

Current Status of Diagnosis and Treatment of Borderline Ovarian Tumors

卵巢交界性肿瘤(borderline ovarian tumor,BOT)是指组织病理学特征和生物学行为介于良性肿瘤和恶性肿瘤之间的一组低度恶性潜能的卵巢肿瘤,具有发病年龄轻、早期发现、预后好的特点,但术前诊断困难,虽然血清肿瘤标志物、盆腔超声及术中快速冰冻病理切片可协助诊断,但准确率不高。手术是治疗BOT的主要方法,近年来,对BOT的手术治疗方式逐渐由根治性手术向保留生育功能的手术转变,术后一般不需辅助化疗。然而,关于其早期诊断、手术方式的选择、术后妊娠结局及预后等问题一直存在广泛争议,就BOT诊断、治疗、预后的研究现状进行综述,以期为今后BOT的临床诊疗及新的诊疗技术研究提供参考。

Borderline ovarian tumors（BOT） is a low malignant potential ovarian tumors which are characterized by histopathologic features and biologic intermediate between clearly benign and frankly malignant ovarian tumors. It has the characteristics of early onset, early detection and good prognosis, but the preoperative diagnosis is difficult. Although the serum tumor markers, pelvic ultrasound and intraoperative frozen biopsy could assist the diagnosis, the accuracy is low. Surgical removal is the main management. In recent years, the surgical treatment of BOT gradually changed from radical operation to fertility preserving surgery,adjuvant chemotherapy is generally unnecessary. However, there has been widespread controversy about its early diagnosis, therapy and prognosis. This article reviews the research status of BOT diagnosis, treatment and prognosis, in order to provide references for the clinical diagnosis and treatment of BOT and new treatment technology research.